deaths (OS)

mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)

versus lenvatinib
pembrolizumab plus lenvatinib vs. lenvatinib 1 certainty unassessable-15%